DxS Appoints David Jackson as Vice President of Business Development and Licensing
Dr. Jackson was most recently with Response Genetics, Inc. as Executive Vice President and has extensive consulting experience in personalized medicine. Before this he was president and chief operating officer at of CryoFluor Therapeutics. During his career Jackson has held positions including private and public company investment analyst, product and corporate development, and Intellectual Property management roles. He holds a PhD in Physiology and Medicine from Boston University School of Medicine, is trained as a US Patent Agent and holds several US securities licenses.
Topics
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.